- Home
- TAYD vs ZNTL Comparison
TAYD vs ZNTL Comparison
Compare TAYD & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAYD
- ZNTL
- Stock Information
- Founded
- TAYD 1955
- ZNTL 2014
- Country
- TAYD United States
- ZNTL United States
- Employees
- TAYD N/A
- ZNTL N/A
- Industry
- TAYD Industrial Machinery/Components
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- TAYD Industrials
- ZNTL Health Care
- Exchange
- TAYD Nasdaq
- ZNTL Nasdaq
- Market Cap
- TAYD 114.6M
- ZNTL 105.8M
- IPO Year
- TAYD N/A
- ZNTL 2020
- Fundamental
- Price
- TAYD $35.47
- ZNTL $1.34
- Analyst Decision
- TAYD
- ZNTL Buy
- Analyst Count
- TAYD 0
- ZNTL 9
- Target Price
- TAYD N/A
- ZNTL $8.69
- AVG Volume (30 Days)
- TAYD 12.2K
- ZNTL 867.6K
- Earning Date
- TAYD 08-14-2025
- ZNTL 08-08-2025
- Dividend Yield
- TAYD N/A
- ZNTL N/A
- EPS Growth
- TAYD 1.48
- ZNTL N/A
- EPS
- TAYD 2.50
- ZNTL N/A
- Revenue
- TAYD $42,796,782.00
- ZNTL $26,865,000.00
- Revenue This Year
- TAYD $15.06
- ZNTL N/A
- Revenue Next Year
- TAYD $8.37
- ZNTL N/A
- P/E Ratio
- TAYD $14.17
- ZNTL N/A
- Revenue Growth
- TAYD N/A
- ZNTL N/A
- 52 Week Low
- TAYD $29.50
- ZNTL $1.01
- 52 Week High
- TAYD $64.50
- ZNTL $9.92
- Technical
- Relative Strength Index (RSI)
- TAYD 47.30
- ZNTL 47.66
- Support Level
- TAYD $33.67
- ZNTL $1.19
- Resistance Level
- TAYD $36.71
- ZNTL $1.67
- Average True Range (ATR)
- TAYD 1.47
- ZNTL 0.11
- MACD
- TAYD -0.34
- ZNTL 0.02
- Stochastic Oscillator
- TAYD 41.57
- ZNTL 33.40
About TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.